June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Characterization of enhanced lipid nanoparticle delivery after photodisruption of the inner limiting membrane
Author Affiliations & Notes
  • Kaat De Clerck
    Lab of General Biochemistry and Physical Pharmacy, Universiteit Gent, Gent, Belgium
  • Helena Vanluchene
    Lab of General Biochemistry and Physical Pharmacy, Universiteit Gent, Gent, Belgium
  • Kevin Braeckmans
    Lab of General Biochemistry and Physical Pharmacy, Universiteit Gent, Gent, Belgium
  • Stefaan De Smedt
    Lab of General Biochemistry and Physical Pharmacy, Universiteit Gent, Gent, Belgium
  • Katrien Remaut
    Lab of General Biochemistry and Physical Pharmacy, Universiteit Gent, Gent, Belgium
  • Karen Peynshaert
    Lab of General Biochemistry and Physical Pharmacy, Universiteit Gent, Gent, Belgium
  • Footnotes
    Commercial Relationships   Kaat De Clerck None; Helena Vanluchene None; Kevin Braeckmans None; Stefaan De Smedt None; Katrien Remaut None; Karen Peynshaert None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2614. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kaat De Clerck, Helena Vanluchene, Kevin Braeckmans, Stefaan De Smedt, Katrien Remaut, Karen Peynshaert; Characterization of enhanced lipid nanoparticle delivery after photodisruption of the inner limiting membrane. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2614.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The inner limiting membrane (ILM) represents a major hurdle for therapeutics to efficiently reach the retina after intravitreal injection. To tackle this issue, we explore indocyanine green (ICG) mediated photodisruption to locally perforate the ILM. In this concept, ICG is delivered to the ILM followed by pulsed laser treatment generating vapor nanobubbles. Upon their collapse, mechanical effects disrupt the ILM paving the way for therapeutics to enter the retina. Given the increasing interest in mRNA therapy to treat retinal diseases, the goal of this ex vivo study is to characterize the enhancement of mRNA lipid nanoparticle (LNP) delivery after photodisruption.

Methods : Luciferase encoding mRNA LNPs (C12-200;DSPC;Cholesterol;DMG-PEG), fluorescently labeled with DiD dye, were synthesized via microfluidic mixing. Physicochemical characterization was performed by use of Dynamic Light Scattering to determine the size and zeta potential. To disrupt the ILM, ICG was applied on top of bovine retinal explants followed by pulsed laser treatment (2ps, 800nm). After photodisruption, explants were cultured and transfected with LNPs (1µg mRNA/explant) for 24h. Finally, cryosections were prepared followed by immunostaining with collagen IV antibodies to investigate ILM integrity as well as retinal penetration of LNPs with confocal microscopy. To evaluate mRNA expression, the bioluminescent signal -resulting from luciferase expression- was measured after 24h of transfection by use of the IVIS equipment.

Results : Confocal microscopy revealed that LNPs (107±8nm, 2.4±1.7mV) were not able to cross the intact ILM since limited retinal penetration was observed in untreated samples. On the contrary, ILM damage provoked by the photodisruption treatment resulted in substantial penetration of LNPs into the inner retinal layers. Strikingly, this enhanced LNP entry furthermore boosted their efficacy since a 5.8±0.9 fold increase in luciferase expression was obtained compared to explants without photodisruption treatment.

Conclusions : This study indicates that the delivery of LNPs can be substantially enhanced by ILM photodisruption. Additionally, the improved retinal LNP penetration led to a significant increase in mRNA expression. Considering these promising results, future experiments will focus on finding the optimal efficacy safety balance as well as exploring realistic target cells for LNP delivery.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×